Phaseline

Targets › BARF1

BARF1: drug programs, companies and trials

2 programs from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: the race on BARF1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Baylor College of MedicineEBV-specific T cells: A (LMP, BARF1 and EBNA1 specific CTLs)
EBV-specific cytotoxic T lymphocytes targeting viral antigens LMP1, LMP2, BARF1, and EBNA1
LMP1, LMP2, BARF1, EBNA1Phase 1Hodgkin's DiseaseMar 2027
Baylor College of MedicineMABEL CTLs
EBV-specific cytotoxic T lymphocytes targeting LMP, BARF-1 and EBNA1 viral antigens
LMP1, BARF1, EBNA1Phase 1Hodgkin DiseaseMar 2029

Conditions

Hodgkin Disease (1) Hodgkin's Disease (1)

Modalities

mixed (1), other (1)

Companies

Baylor College of Medicine (2)

Related targets

LMP1 (2) EBNA1 (2) LMP2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.